OMDA — Stock Analysis (Atlas)

Date: 2026-05-01 Quarter analyzed: Q4 FY2025 (Dec-25); Q1 FY2026 reports May 7, 2026 Market cap: ~0.79B|EV: 0.57B | EV/TTM Rev: ~0.55x | EV/FY26 Rev: ~1.8x | Revenue growth: +58.1% Q4 YoY, +53.2% FY

Verdict

OMDA passes the qualification gate cleanly and trades at a structural discount to its growth profile. Q4 FY25 marks a triple inflection: revenue re-acceleration (49.5% → 58.1% YoY), first GAAP-profitable quarter, and an EBITDA milestone delivered "a year ahead" of the IPO roadshow. At ~2.5x P/S and 0.55x EV/TTM revenue with a 53% growth rate and a Rule of 40 score of ~57, the market is paying SaaS-laggard prices for a hyper-growth chronic-disease platform — a mispricing I attribute to post-IPO drift, the headline +22% FY26 guidance optic, and unresolved GLP-1 substitution fear. The conservative FY26 guide explicitly excludes three real upside levers (GLP-1 prescribing, FlexCare, cholesterol). Conviction: 4/5 — a high-quality, asymmetric long with the May 7 print as the proximate catalyst.

Qualification Gate

All gating criteria pass. Dilution is not a clean comparable in the IPO year; share count went 8M (private) → 22M Q2 → 57.7M Q3 → 63.9M Q4 due to IPO conversion, not organic dilution.

Six-Factor Score

Composite read: 5 of 6 factors are squarely positive; "Dominance" is the only factor with a meaningful debate, and it is well-priced.

The Numbers — 8-Quarter Grid

| | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---| | Revenue ($m) | 35.1 | 41.2 | 45.5 | 48.0 | 54.9 | 61.4 | 68.0 | **75.8** | | QoQ % | — | +17.4% | +10.4% | +5.4% | +14.4% | +11.8% | +10.7% | **+11.5%** | | YoY % | — | — | — | — | +56.4% | +49.0% | +49.5% | **+58.1%** | | GM [GAAP] | 49.6% | 60.3% | 62.8% | 67.0% | 58.1% | 65.7% | 66.3% | **70.8%** | | GM [Non-GAAP] | 52.4% | 62.8% | 65.2% | 69.4% | 60.3% | 67.7% | 68.2% | **72.6%** | | Op Margin [GAAP] | -51.3% | -24.3% | -18.7% | -14.8% | -15.3% | -7.0% | -3.7% | **+4.3%** | | Adj EBITDA Margin | — | -16.5% | -11.2% | -7.3% | — | -0.3% | +3.5% | **+11.2%** | | Net Margin [GAAP] | -54.1% | -26.0% | -20.2% | -17.2% | -17.3% | -8.6% | -4.7% | **+6.8%** | | EPS diluted [GAAP] | n/a* | (1.40) | (1.18) | (1.04) | n/a* | (0.24) | (0.06) | **+0.08** | | Total Members (k) | — | 495 | 543 | 571 | — | 752 | 831 | **886** | | Members YoY | — | — | — | — | — | +51.9% | +53.0% | **+55.2%** | | FCF ($m) | — | — | — | -7.5 | — | — | +8.2 | +20.0 |

*Pre-IPO EPS not comparable due to preferred/common conversion.

Thesis / Anti-Thesis

Thesis (long case)

1. Multi-condition chronic-disease platform with proven scale — 886K active members, 25M+ covered lives, 2,000 employer/payer clients, top-2 PBM alignment. Three core programs (weight, diabetes, hypertension) all growing >40% YoY in FY25; cholesterol added in early rollout with a 300K+ employee customer.
2. GLP-1 inflection is real and quantified — Cumulative GLP-1 members tripled to 150K+ in FY25 (+100K added in a single year). Internal evidence (84% 24-week persistence, 18% weight loss vs 12% benchmark, 0.8% post-discontinuation regain at 12 months) supports the "companion care is required" framing. Now prescribing GLP-1s directly via FlexCare — full-stack obesity platform.
3. Profitability inflection delivered ahead of schedule — Q4 FY25 first GAAP-profitable quarter (+5.2MNI, +3.3M op income); FY25 Adj EBITDA flipped to +6.5Mfrom−29.4M. CEO: "a year ahead of IPO roadshow projections." Incremental EBITDA conversion rate disclosed at 40%.
4. Conservative FY26 guidance with embedded upside — Mid $317M (+22%) explicitly assumes no enrollment-yield improvement, no new product scaling, no ARPU expansion. With FY25 actual growth at +53% and Q4 exit run-rate at +58%, the bar is unusually low. Sell-side consensus already at $74-76M for Q1 implies +35-38% YoY — 13-16pp above guide implied.
5. Valuation is asymmetric — 2.5x P/S, 0.55x EV/TTM revenue, 1.8x EV/FY26 revenue. Rule of 40 = 57. PEG fractional. Net cash $222M (28% of market cap). Stock at $11.41 vs $19 IPO — the multiple compression is fully done relative to digital-health comps.
6. Capital structure is clean — Zero debt (term loan repaid in FY25), 222Mcash, FY25FCF+12.4M (4.8% margin) inflecting to 26% margin in Q4. Self-funded growth from here.

Anti-Thesis (bear case)

1. GLP-1 substitution risk is the central unresolvable — If GLP-1 medications "just work," the value of behavior-change coaching erodes. Omada's claim that coaching is required for medication persistence (84% at 24 weeks) and post-discontinuation maintenance (0.8% regain) is compelling but the post-discontinuation sample is n=95 — too small to bet a thesis on. The PREDICTS RCT will eventually adjudicate but is years from readout.
2. Customer experience bifurcation — App Store 4.7/5 at scale (88K reviews) is genuine, but the persistent BBB/Google complaints about (a) billing confusion and (b) GLP-1 medication-access delays gated by Omada onboarding are a process risk. The latter scales linearly with GLP-1 enrollment — exactly the wedge Omada is leaning into.
3. Member retention is undisclosed — No NRR, no churn rate, no cohort persistence metric. ARPU disclosed at ~$300/year (revenue/members), but a single-year member relationship would invalidate LTV models.
4. +22% guidance optic — The market may be reading guidance literally. If management is in fact being conservative as claimed, this discounts; if guidance is honest, the deceleration is real (53% → 22%) and the multiple compression is justified.
5. Competitive density — Noom moving into B2B; Virta in T2D; Hinge in MSK; Teladoc/Livongo distressed but still incumbent. Amazon Pharmacy, Virgin Pulse, and corporate wellness all touching the GLP-1 employer benefit. The window for Omada to widen its lead is 18-24 months.
6. CMO departure (Mar-25) — Carolyn Jasik to Verily is a notable clinical-leadership loss for a company whose moat is clinical outcomes. Not a thesis-break alone but a marker.
7. Health Coach pay (3.1/5 Glassdoor) — Frontline clinical labor is the unit of production. If attrition rises, member experience degrades — a slow-burn risk if not addressed.

Resolution

The thesis wins on the math. At 0.55x EV/TTM revenue with 53% growth and accelerating, GAAP profitability achieved, and ~$0.6B EV against $260M revenue + $317M FY26 guide, the bear case has to break the "GLP-1 needs coaching" claim AND assume management is sandbagging the conservative framing. Both can be true in part without breaking the long. The mathematical asymmetry (downside ~$7-9 implies ~30-40% loss; upside 15 − 23implies + 30 − 1001B name.

Leading Indicators

Bullish divergence: Every single leading indicator is accelerating into the FY26 guide. The +22% revenue guide is in direct tension with +55% member YoY and +200% GLP-1 YoY. Either guide is conservative as claimed (most likely), or member growth must collapse in H1 FY26. The May 7 Q1 print will be the first clean read.

Watch for divergence: If Q1 member adds <40K (vs Q4's +55K), or if GLP-1 enrollments don't sustain ~25K+ per quarter, the bear case strengthens.

Scuttlebutt Findings

Highlights from the scuttlebutt stage (full file: stages/scuttlebutt/OMDA/2026-05-01.md).

• Customer sentiment is bifurcated. App Store 4.7/5 (88K reviews) is the dominant signal — large, engaged, positive. The 2.6/5 Google rating (62 reviews) and BBB complaints concentrate on (a) billing confusion / opaque eligibility and (b) GLP-1 medication-access delays caused by employer-mandated Omada onboarding. The latter is the higher-stakes risk: it scales with GLP-1 enrollment.
• Employee sentiment is materially positive. Glassdoor 4.2/5 (245 reviews), 22% above healthcare industry average; 83% recommend, 86% positive outlook. Health Coach pay is the soft spot (3.1/5) — frontline clinical labor risk.
• Clinical evidence is the moat. 30+ peer-reviewed publications, ANSWERS observational program, PREDICTS RCT in progress. ObesityWeek 2025 data (84% GLP-1 persistence at 24 weeks; 0.8% post-discontinuation regain) is the strongest objective evidence supporting the companion-care thesis. Caveat: post-discontinuation n=95.
• Competitor field is real but not winning. Teladoc/Livongo distressed (massive goodwill writedowns); Noom struggling B2B; Virta narrow (T2D only); Hinge adjacent (MSK only). Omada's multi-condition + GLP-1 prescribing breadth is uniquely positioned today, but the moat erodes if competitors replicate prescribing in 18-24 months.
• Management posture is founder-led, long-tenured, well-capitalized. Sean Duffy 14 years at the helm; 4.1% ownership; A16Z, Revelation, USVP backing didn't sell at IPO. CMO departure to Verily (Mar-25) is the personnel watch item.
• Hiring posture: managed scaling, not hypergrowth. ~24 open roles for an 886K-member company. Heavy weighting toward B2B platform, Salesforce/CSM, finance/admin, data — consistent with profitable scaling. Absence of frontline coach hiring is either AI leverage or member growth moderation; cannot be distinguished from the outside.
• Industry tailwind is genuine. MAHA policy environment, GLP-1 wave, employer chronic-disease cost pressure. Sell-side consensus 80% Buy/Strong Buy, no Sell ratings.

Valuation Context

The valuation table doesn't tell a "fair" story — it tells a "discount" story. OMDA prices like a 25% grower; it actually grew 53% in FY25 and exited Q4 at 58%.

Fair value framework (from valuation-context, mid-cycle):

• Bear (+22% sustained, 1.5-2.0x EV/Rev): $4.35-7.05 → -38 to -62% downside
• Base (40-45% growth, 2.5-3.5x EV/Rev): $9.76-15.20 → -14% to +33%
• Bull (50%+ with GLP-1 scaling, 3.5-5.0x EV/Rev): $15.20-23.35 → +33% to +105%

My assessment: Base+ case is mathematically dominant given Q4 exit-rate momentum. Asymmetry favors long.

Platform & Secular Position

• Secular tailwinds (3 stacking): (1) GLP-1 wave projected at $100B by end-of-decade — Omada is the only public, multi-condition, prescribing-capable companion-care play; (2) employer cost pressure on chronic disease management intensifying; (3) MAHA / chronic disease policy environment is bipartisan tailwind.
• Platform vs point solution: Genuine platform. Multi-condition (weight, diabetes, hypertension, MSK, cholesterol, GLP-1 prescribing) sold to a single throat at the employer — not a point app. Cross-sell is happening among existing enterprise customers; cholesterol seeded in a 300K+ employee customer.
• TAM penetration: 25M covered lives addressed against a US employer-insured population of ~150M+. ~17% reach with ~3.5% activation (886K members). The covered-lives → enrolled-members funnel is the long-term lever; Omada disclosed +24% YoY enrollment-rate improvement in FY25, all UX-driven not paid-media-driven.
• Data moat: "Tens of millions of care team messages, billions of data points, more than a decade of clinical outcomes" — credible. Whether this becomes a true AI/ML moat (training proprietary models for outcomes prediction) or remains an evidence repository for sales/clinical positioning is the open question. Omada Spark (nutritional decision support) and Meal Map (food tracking) are the early productized AI deliverables.

Key Risks

1. GLP-1 substitution unresolved. If GLP-1s alone deliver durable weight loss without coaching, employer demand for Omada companion programs collapses. PREDICTS RCT is years from readout; n=95 post-discontinuation data is the strongest objective evidence today.
2. Member retention undisclosed. No NRR, no churn, no cohort persistence rate. Single-year member relationships would break the LTV model. Worth pressing on May 7 call.
3. GLP-1 access friction at scale. Customer complaints concentrate on Omada-onboarding-as-gate to medication. As GLP-1 enrollments multiply, this UX risk scales linearly and could trigger backlash or employer policy reversals.
4. Competitive replication of GLP-1 prescribing. Noom, Virta, and corporate wellness platforms can build prescribing capability within 18-24 months. Omada's differentiation window is finite.
5. Health Coach attrition risk. Frontline labor pay rated 3.1/5; clinical coaches are scarce. If churn accelerates, member outcomes degrade — slow-burn risk.

Key Catalysts

1. Q1 FY26 earnings (May 7, 2026). First read on FY26 trajectory. Consensus 74 − 76M(+35 − 3867M (+22%). Beat unlocks multiple expansion; in-line confirms guidance is honest deceleration.
2. GLP-1 prescribing rollout scaling. Direct prescribing + FlexCare cash-pay are explicit upside levers excluded from FY26 baseline. Any quantified contribution in 1H FY26 is a re-rate catalyst.
3. Cholesterol program scaling. Seeded with 300K+ employee customer; broader rollout in FY26 adds a 4th >40%-growth program line.
4. PREDICTS / ANSWERS clinical readouts. Prospective RCT data on GLP-1 companion care would address the central bear claim definitively.
5. Member retention disclosure. If management discloses NRR or cohort retention metrics on May 7, it reduces the "unknown unknowns" discount.

Position Disclosure

Atlas does not hold positions. This is a baseline analysis for downstream personas.

Filed by Atlas. Other personas should treat this as their starting baseline and add their own framework's interpretation.